Welcome to our dedicated page for GASE ENERGY news (Ticker: GASE), a resource for investors and traders seeking the latest updates and insights on GASE ENERGY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GASE ENERGY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GASE ENERGY's position in the market.
GASE Energy, Inc. (OTC-PINK:GASE) has signed a Definitive Acquisition Agreement with Btab Group Inc. to acquire five subsidiaries for a robust transaction valued at over $75 million. The business combination is set to generate annual revenues exceeding $11 million and approximately $1 million in EBITDA. GASE will issue 63 million new common shares and 5 million Class B shares to Btab, giving Btab the right to nominate three directors to GASE’s board. Post-acquisition, GASE shareholders will control around 20% of the combined entity.
Gase Energy, Inc. (OTCIQ: GASE) will present at the Emerging Growth Conference on March 2, 2022, from 1:00 to 1:30 PM Eastern. This live, interactive online event allows investors to engage with CEO Sean Martin and Judson Boothe, CEO of Sanatio Bio. The presentation will include a Q&A session for attendees. An archived webcast will be available post-event for those unable to attend live. The Emerging Growth Conference aims to showcase public companies and their potential growth to a wide audience of investors.
Gase Energy (OTCIQ:GASE) has signed a second letter of intent to acquire Sanatio BioScience Inc., which specializes in modular therapeutics for antiviral and anticancer applications. The proprietary platform targets specific cell types to enhance antiviral activities, with a focus on COVID-19 and potential future threats. GASE's CEO, Sean Martin, emphasized the synergy between antiviral and vaccine solutions, while Sanatio's CEO, Judson Boothe, noted their ability to quickly pivot their therapeutic focus. No guarantees of acquisition completion were provided, but potential synergies with another company, Curadox, were mentioned.
Gase Energy, Inc. (OTCIQ: GASE) has signed a Letter of Intent to merge with Curadox Biopharma, Inc. (CBI), a company focused on developing drugs targeting drug-resistant cancer cells. CEO Sean Martin expressed excitement about transitioning GASE into the biotechnology sector and highlighted CBI's promising technology, which has shown efficacy in clinical trials and has FDA Compassionate Use approval. CBI's innovative TRF-DOX conjugate aims to specifically target abnormal cells, providing a minimally toxic treatment option for cancer patients and potentially qualifying for orphan drug status.
FAQ
What is the market cap of GASE ENERGY (GASE)?
